ONCOCYTE CORP

Profile

Company Names

ONCOCYTE CORP

Addresses

15 CUSHING, IRVINE, CA 92618

1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA, CA 94501

1301 HARBOR BAY PARKWAY, SUITE 100, ALAMEDA, CA 94502

Phone Numbers

949-409-7600
510-775-0515
510-521-3390

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY

Year Incorporated:

> 5 years ago

State Incorporated:

CALIFORNIA

Total Amount Raised:

$82,961,564.00

Number of Funding Rounds:

9
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
9
2025-02-10 
$21,743,597.00 
$21,743,597.00 
$0.00 
Equity 
8
2024-10-02 
$10,204,262.00 
$10,204,262.00 
$0.00 
Equity 
7
2024-04-11 
$15,807,692.00 
$15,807,692.00 
$0.00 
Equity 
6
2021-04-15 
$3,006,577.00 
$17,500,000.00 
$14,493,423.00 
Equity 
5
2021-02-24 
$5,000,000.00 
$5,000,000.00 
$0.00 
Equity 
4
2020-01-31 
$5,000,000.00 
$11,000,000.00 
$6,000,000.00 
Equity 
3
2016-08-29 
$10,549,997.00 
$10,549,997.00 
$0.00 
Equity 
2
2015-09-29 
$8,349,439.00 
$11,350,738.00 
$3,001,299.00 
Equity 
1
2015-05-08 
$3,300,000.00 
$3,300,000.00 
$0.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
RONALD 
 
ANDREWS 
EXECUTIVE OFFICER, DIRECTOR
ONCOCYTE CORP
RONALD 
A 
ANDREWS 
EXECUTIVE OFFICER, DIRECTOR
ONCOCYTE CORP
WILLIAM 
 
ANNETT 
DIRECTOR, EXECUTIVE OFFICER
ONCOCYTE CORP
ANDREW 
 
ARNO 
DIRECTOR
UNTERBERG TECHNOLOGY PARTNERS, L.P.   |  MERRIMAN CURHAN FORD GROUP, INC.   |  SMITH MICRO SOFTWARE INC   |  ASTERIAS BIOTHERAPEUTICS, INC.   |  ONCOCYTE CORP   |  COMHEAR, INC.   |  SMITH MICRO SOFTWARE, INC   |  INDEPENDA, INC.   |  SMITH MICRO SOFTWARE, INC.
ANDY 
 
ARNO 
DIRECTOR
ONCOCYTE CORP   |  22ND CENTURY GROUP, INC.   |  INDEPENDA, INC.
DON 
 
BAILEY 
DIRECTOR
SAXON OIL CO LTD   |  ONCOCYTE CORP
JENNIFER 
LEVIN 
CARTER 
DIRECTOR
N-OF-ONE THERAPEUTICS, INC.   |  ONCOCYTE CORP
KAREN 
B. 
CHAPMAN 
EXECUTIVE OFFICER
ONCOCYTE CORP
MELINDA 
 
GRIFFITH 
DIRECTOR
CARDIODX INC   |  ONCOCYTE CORP
ANDREA 
 
JAMES 
EXECUTIVE OFFICER
ONCOCYTE CORP
ALFRED 
 
KINGSLEY 
DIRECTOR
ONCOCYTE CORP
ALFRED 
D 
KINGSLEY 
DIRECTOR
BIOTIME INC   |  RECYTE THERAPEUTICS, INC.   |  ASTERIAS BIOTHERAPEUTICS, INC.   |  ONCOCYTE CORP
ALFRED 
D. 
KINGSLEY 
DIRECTOR
ONCOCYTE CORP   |  ASCENDANCE BIOTECHNOLOGY, INC.   |  AGEX THERAPEUTICS, INC.
ANDREW 
 
LAST 
DIRECTOR
ONCOCYTE CORP   |  SOURCE DONOR INC.
ANDREW 
J 
LAST 
DIRECTOR
ONCOCYTE CORP
MITCH 
 
LEVINE 
EXECUTIVE OFFICER
ROCKMORE GLOBAL (US), LP   |  ONCOCYTE CORP   |  SMART HEALTH DIAGNOSTICS CO   |  IMMUNOPRECISE ANTIBODIES LTD.   |  RPM-ONE, INC.
MITCHELL 
 
LEVINE 
EXECUTIVE OFFICER
FORECADDIE PARTNERS, LTD.   |  ONCOCYTE CORP
JAMES 
 
LIU 
EXECUTIVE OFFICER, DIRECTOR
MONEYPARK, INC.   |  SINDEO, INC.   |  SHIFTGIG, INC.   |  ONERENT, INC.   |  ZADIG CAPITAL PARTNERS LP   |  ONCOCYTE CORP
KRISTINE 
C. 
MECHEM 
EXECUTIVE OFFICER
ONCOCYTE CORP
ADITYA 
 
MOHANTY 
DIRECTOR
ONCOCYTE CORP
ALBERT 
 
PARKER 
EXECUTIVE OFFICER
ONCOCYTE CORP
ROBERT 
W. 
PEABODY 
EXECUTIVE OFFICER, DIRECTOR
ONCOCYTE CORP
CAVAN 
 
REDMOND 
DIRECTOR
ONCOCYTE CORP
JOSHUA 
 
RIGGS 
EXECUTIVE OFFICER, DIRECTOR
ONCOCYTE CORP
DOUGLAS 
T 
ROSS 
EXECUTIVE OFFICER
ONCOCYTE CORP
LOUIS 
 
SILVERMAN 
DIRECTOR
ADVANCED ICU CARE, INC.   |  G4 CAPITAL PARTNERS III, LP   |  G4 REIT LLC   |  G4 CAPITAL PARTNERS IV, LP   |  G4 CAPITAL PARTNERS V, LP   |  ONCOCYTE CORP   |  G4 CAPITAL PARTNERS VI, LP
RUSSELL 
 
SKIBSTED 
EXECUTIVE OFFICER
AEOLUS PHARMACEUTICALS, INC.   |  ONCOCYTE CORP   |  AGEX THERAPEUTICS, INC.   |  ALIMERA SCIENCES INC
PADMAVATHI 
 
SUNDAR 
EXECUTIVE OFFICER
ONCOCYTE CORP
JOSEPH 
 
WAGNER 
EXECUTIVE OFFICER, DIRECTOR
POWERMAG, LLC   |  ONCOCYTE CORP   |  NOTABLE LABS, INC.
MICHAEL 
 
WEST 
DIRECTOR
SOCRATIVE, INC.   |  ONCOCYTE CORP   |  MDVALUATE, INC.   |  ORTELLIGENCE, INC.   |  DB AVIATOR EUROPE, LP   |  PACE SURGICAL, INC.
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2025-02-24
D
Link
BIOTECHNOLOGY 
IN VITRO + IN VIVO DIAGNOSTIC SUBSTANCES [2835] 
DECLINE TO DISCLOSE 
Equity 
2025-02-10 
2024-10-08
D
Link
BIOTECHNOLOGY 
IN VITRO + IN VIVO DIAGNOSTIC SUBSTANCES [2835] 
DECLINE TO DISCLOSE 
Equity 
2024-10-02 
2024-04-25
D
Link
BIOTECHNOLOGY 
IN VITRO + IN VIVO DIAGNOSTIC SUBSTANCES [2835] 
DECLINE TO DISCLOSE 
Equity 
2024-04-11 
2021-04-29
D
Link
BIOTECHNOLOGY 
IN VITRO + IN VIVO DIAGNOSTIC SUBSTANCES [2835] 
DECLINE TO DISCLOSE 
Equity 
2021-04-15 
2021-03-08
D
Link
BIOTECHNOLOGY 
IN VITRO + IN VIVO DIAGNOSTIC SUBSTANCES [2835] 
DECLINE TO DISCLOSE 
Equity 
2021-02-24 
2020-02-11
D
Link
BIOTECHNOLOGY 
IN VITRO + IN VIVO DIAGNOSTIC SUBSTANCES [2835] 
DECLINE TO DISCLOSE 
Equity 
2020-01-31 
2016-09-09
D
Link
BIOTECHNOLOGY 
IN VITRO + IN VIVO DIAGNOSTIC SUBSTANCES [2835] 
DECLINE TO DISCLOSE 
Equity 
2016-08-29 
2015-10-15
D
Link
BIOTECHNOLOGY 
IN VITRO + IN VIVO DIAGNOSTIC SUBSTANCES [2835] 
NO REVENUES 
Equity 
2015-09-29 
2015-05-14
D
Link
BIOTECHNOLOGY 
 
NO REVENUES 
Equity 
2015-05-08 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#
NONE
NONE
NEEDHAM + COMPANY, LLC
000016360
NONE
NONE
COWEN + COMPANY, LLC
7616